A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+metastatic breast cancer (MBC)

被引：0
作者：
Rugo, H. S.
Franco, S.
Munster, P.
Stopeck, A.
Ma, W.
Lyandres, J.
Lahiri, S.
Arbushites, M.
Koehler, M.
Dickler, M. N.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Mem Canc Inst, Hollywood, FL USA
[3] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[4] Arizona Canc Ctr, Tucson, AZ USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] GlaxoSmithKline, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A PHASE II EVALUATION OF LAPATINIB (L) AND BEVACIZUMAB (B) IN HER2+METASTATIC BREAST CANCER (MBC)
    Dickler, M.
    Franco, S.
    Stopeck, A.
    Ma, W.
    Lyandres, J.
    Lahiri, S.
    Arbushites, M.
    Koehler, M.
    Rugo, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 65 - 65
  • [2] Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC)
    Dickler, M.
    Franco, S.
    Stopeck, A.
    Ma, W.
    Nulsen, B.
    Lyandres, J.
    Melisko, M.
    Lahiri, S.
    Arbushites, M.
    Koehler, M.
    Rugo, H. S.
    CANCER RESEARCH, 2009, 69 (02) : 242S - 242S
  • [3] TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC)
    Lin, N. U.
    Mayer, I. A.
    Hobday, T. J.
    Falkson, C. I.
    Dees, E. C.
    Nanda, R.
    Krop, I. E.
    Rimawi, M. F.
    Wolff, A. C.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC)
    Lin, N. U.
    Mayer, I. A.
    Najita, J. S.
    Hobday, T. J.
    Falkson, C. I.
    Dees, E. C.
    Rimawi, M. F.
    Nanda, R.
    Gelman, R. S.
    Josephs, K.
    Richardson, A.
    Flores, L.
    Van Den Abbeele, A. D.
    Yap, J. T.
    Arteaga, C. L.
    Wolff, A. C.
    Krop, I. E.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Duration of lapatinib (L)-based therapy in HER2+metastatic breast cancer (MBC) in a single institution.
    Morales, Serafin
    Cud''s, Ariadna Gasol
    Salud, Antonia
    Aguirre Ortega, Elena Maria
    Derabrain, Noema A. Tuset
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Lapatinib (L) plus capecitabine (C) in HER2+metastatic breast cancer (MBC): exploratory analyses by prior therapy
    Crown, J.
    Casey, M. A.
    Cameron, D.
    Newstat, B.
    Stein, S. H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 285 - 285
  • [7] Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+metastatic breast cancer (MBC)
    Kalinsky, Kevin
    Lee, Shing
    Tiersten, Amy
    Makower, Della F.
    Cigler, Tessa
    Franks, Lauren
    Mundi, Prabhjot
    Chi, Dow-Chung
    Blumberg, Lauren
    Sender, Naomi
    Galazyn, Magdalena
    Hosi, Kristina
    Goel, Anupama
    Klein, Paula
    Andreopoulou, Eleni
    Sparano, Joseph
    Crew, Katherine D.
    Califano, Andrea
    Silva, Jose
    Hershman, Dawn L.
    CANCER RESEARCH, 2020, 80 (04)
  • [8] Phase II study of lapatinib and tegafur combination efficacy for the treatment of HER2+metastatic breast cancer.
    Manikhas, Alexey
    Sharvashidze, Ineza O.
    Kotkova, Tatjana N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] A phase II study with lead-in safety cohort of cabazitaxel (C) plus lapatinib (L) as therapy for HER2+metastatic breast cancer (MBC) with intracranial metastases (mets)
    Yardley, Denise A.
    Hainsworth, John D.
    Hamilton, Erika Paige
    Hart, Lowell L.
    Shastry, Mythili
    DeBusk, Laura M.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Rugo, Hope S.
    Chien, A. Jo
    Franco, Sandra X.
    Stopeck, Alison T.
    Glencer, Alexa
    Lahiri, Soumi
    Arbushites, Michael C.
    Scott, Janet
    Park, John W.
    Hudis, Clifford
    Nulsen, Ben
    Dickler, Maura N.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 13 - 20
12345